Evaluation of the Safety and Effectiveness of BOTOX® (Clostridium Botulinum Toxin Type A) in the Treatment of Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity or Overactive Bladder: A Post-marketing Surveillance Study inKorea

First published 08/11/2016

Last updated 20/02/2024

EU PAS number:

EUPAS16140

Study

Finalised

Documents

Study protocol

Initial protocol

(Korea) Botox in NDO NOV2013

English (693.4 KB - PDF) View document

Study results

BtxNDOOAB_Re-examination report_Eng_V1 0_clean_Final_20161202_Redacted

English (4.89 MB - PDF) View document

Study report

Other information

Secondary tabs